Prevail Therapeutics, an early stage biotech developing gene therapies for neurodegenerative diseases, announced terms for its IPO on Monday.
The New York, NY-based company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Prevail Therapeutics would command a fully diluted market value of $672 million.
Prevail Therapeutics was founded in 2017 and plans to list on the Nasdaq under the symbol PRVL. Morgan Stanley, BofA Merrill Lynch and Cowen are the joint bookrunners on the deal. It is expected to price during the week of June 17, 2019.
